Anti-BRCA2 抗体 (ab9143)
Key features and details
- Rabbit polyclonal to BRCA2
- Suitable for: WB, IP
- Reacts with: Human
- Isotype: IgG
製品の概要
-
製品名
Anti-BRCA2 antibody
BRCA2 一次抗体 製品一覧 -
製品の詳細
Rabbit polyclonal to BRCA2 -
由来種
Rabbit -
アプリケーション
適用あり: WB, IPmore details -
種交差性
交差種: Human
交差が予測される動物種: Chimpanzee, Gorilla -
免疫原
Synthetic peptide corresponding to Human BRCA2.
-
ポジティブ・コントロール
- IP: HEK-293T cell lysate. WB: HEK293T, OVCAR-3, Hep-G2, K-562, Jurkat, HeLa, U2OS, and MCF-7 whole cell lysates.
-
特記事項
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
バッファー
pH: 7
Preservative: 0.09% Sodium azide
Constituents: 0.021% PBS, 1.764% Sodium citrate, 1.815% Tris -
Concentration information loading...
-
精製度
Immunogen affinity purified -
特記事項(精製)
Antibodies were affinity purified using the peptide immobilized on solid support. Antibody concentration was determined by extinction coefficient: absorbance at 280 nmof 1.4 equals 1.0 mg of IgG. -
ポリ/モノ
ポリクローナル -
アイソタイプ
IgG -
研究分野
関連製品
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab9143の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
WB | (1) |
1/2000 - 1/10000. Predicted molecular weight: 384 kDa.
|
IP |
Use a concentration of 2 - 10 µg/ml.
|
特記事項 |
---|
WB
1/2000 - 1/10000. Predicted molecular weight: 384 kDa. |
IP
Use a concentration of 2 - 10 µg/ml. |
ターゲット情報
-
機能
Involved in double-strand break repair and/or homologous recombination. Binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA (ssDNA). Acts by targeting RAD51 to ssDNA over double-stranded DNA, enabling RAD51 to displace replication protein-A (RPA) from ssDNA and stabilizing RAD51-ssDNA filaments by blocking ATP hydrolysis. May participate in S phase checkpoint activation. Binds selectively to ssDNA, and to ssDNA in tailed duplexes and replication fork structures. -
組織特異性
Highest levels of expression in breast and thymus, with slightly lower levels in lung, ovary and spleen. -
関連疾患
Defects in BRCA2 are a cause of susceptibility to breast cancer (BC) [MIM:114480]. A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.
Defects in BRCA2 are the cause of pancreatic cancer type 2 (PNCA2) [MIM:613347]. It is a malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.
Defects in BRCA2 are a cause of susceptibility to breast-ovarian cancer familial type 2 (BROVCA2) [MIM:612555]. A condition associated with familial predisposition to cancer of the breast and ovaries. Characteristic features in affected families are an early age of onset of breast cancer (often before age 50), increased chance of bilateral cancers (cancer that develop in both breasts, or both ovaries, independently), frequent occurrence of breast cancer among men, increased incidence of tumors of other specific organs, such as the prostate.
Defects in BRCA2 are the cause of Fanconi anemia complementation group D type 1 (FANCD1) [MIM:605724]. It is a disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair.
Defects in BRCA2 are a cause of glioma type 3 (GLM3) [MIM:613029]. Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. -
配列類似性
Contains 8 BRCA2 repeats. -
翻訳後修飾
Phosphorylated by ATM upon irradiation-induced DNA damage.
Ubiquitinated in the absence of DNA damage; this does not lead to proteasomal degradation. In contrast, ubiquitination in response to DNA damage leads to proteasomal degradation. - Information by UniProt
-
参照データベース
- Entrez Gene: 675 Human
- Omim: 600185 Human
- SwissProt: P51587 Human
- Unigene: 34012 Human
-
別名
- BRCA 2 antibody
- BRCA1/BRCA2 containing complex subunit 2 antibody
- Brca2 antibody
see all
画像
-
BRCA2 was immunoprecipitated from HEK293T whole cell lysate (1 mg per IP reaction, 20% loaded) with ab9143 at 6 µg per reaction. Western blot was performed on the immunoprecipitate using ab9143 at 0.01 µg/mL.
Lane 1: ab9143 IP in HEK293T whole cell lysate.
Lane 2: ab9143 IP in HEK293T whole cell lysate.
Lane 3: Control IgG in HEK293T whole cell lysate.
Detection: Chemiluminescence with an exposure time of 30 seconds
-
All lanes : Anti-BRCA2 antibody (ab9143) at 0.1 µg/ml
Lane 1 : HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate
Lane 2 : OVCAR-3 (human ovary epithelial adenocarcinoma cell line) whole cell lysate
Lane 3 : HepG2 (human liver hepatocellular carcinoma cell line) whole cell lysate
Lane 4 : K562 (human chronic myelogenous leukemia cell line from bone marrow) whole cell lysate
Lane 5 : Jurkat (human T cell leukemia cell line from peripheral blood) whole cell lysate
Lane 6 : HeLa (human epithelial cell line from cervix adenocarcinoma) whole cell lysate
Lane 7 : U-2 OS (human bone osteosarcoma epithelial cell line) whole cell lysate
Lane 8 : MCF7 (human breast adenocarcinoma cell line) whole cell lysate
Lysates/proteins at 50 µg per lane.
Predicted band size: 384 kDa
Exposure time: 3 minutes
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (6)
ab9143 は 6 報の論文で使用されています。
- Caburet S et al. Homozygous hypomorphic BRCA2 variant in primary ovarian insufficiency without cancer or Fanconi anaemia trait. J Med Genet N/A:N/A (2020). PubMed: 32482800
- Hung LY et al. Microfluidic platforms for rapid screening of cancer affinity reagents by using tissue samples. Biomicrofluidics 12:054108 (2018). PubMed: 30344835
- Schaaf L et al. Hyperthermia Synergizes with Chemotherapy by Inhibiting PARP1-Dependent DNA Replication Arrest. Cancer Res 76:2868-75 (2016). PubMed: 27013194
- Orthwein A et al. A mechanism for the suppression of homologous recombination in G1 cells. Nature 528:422-6 (2015). PubMed: 26649820
- Suzuki S et al. Inhibition of post-translational N-glycosylation by HRD1 that controls the fate of ABCG5/8 transporter. Sci Rep 4:4258 (2014). Human . PubMed: 24584735
- Hussain S et al. Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1. Hum Mol Genet 12:2503-10 (2003). ICC/IF ; Human . PubMed: 12915460